参考文献
[1]Chen W,Zheng R,Baade P D,et al.Cancer Statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2]Siegel R L,Miller K D,Jemal A.Cancer Statistics,2017[J].CA Cancer J Clin,2017,67:7-30.
[3]Van den Bosch T,Coosemans A,Morina M,et al.Screening for uterine tumours[J].Best Pract Res Clin Obstet Gynaecol,2012,26(2):257-266.
[4]Obermair A,Youlden D R,Young J P,et al.Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma[J].Int J Cancer,2010(127):2678-2684.
[5]Katz V L.Diagnostic procedures.Imaging,endometrial sampling,endoscopy:indications and contraindications,complications.In:Katz VL,Lentz GM,Lobo RA,Gershenson D M,eds.Comprehensive Gynecology[M].5th ed.Philadelphia,Pa:Mosby,2007:chap 11.
[6]Resnick K E,Hampel H,Fishel R,et al.Current and emerging trends in Lynch syndrome identification in women with endometrial cancer[J].Gynecol Oncol,2009(114):128-134.
[7]Win A K,Lindor N M,Winship I,et al.Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome[J].J Natl Cancer Inst,2013(105):274-279.
[8]Chan J K,Sherman A E,Kapp D S,et al.Influence of gynecologic oncologists on the survival of patients with endometrial cancer[J].J Clin Oncol,2011(29):832-838.
[9]Doll K M,Tseng J,Denslow S A,et al.High-grade endometrial cancer:revisiting the impact of tumor size and location on outcomes[J].Gynecol Oncol,2014(132):44-49.
[10]Benedetti Panici P,Basile S,Salerno M G,et al.Secondary analyses from a randomized clinical trial:age as the key prognostic factor in endometrial carcinoma[J].Am J Obstet Gynecol,2014(210):363,e361-363,e310.
[11]Ortashi O,Jain S,Emannuel O,et al.Evaluation of the sensitivity,specificity,positive and negative predictive values of preoperative magnetic resonance imaging for staging endometrial cancer.A prospective study of 100 cases at the Dorset Cancer Centre[J].Eur J Obstet Gynecol Reprod Biol,2008(137):232-235.
[12]Patsner B,Orr J W,Jr.,Mann W J,Jr.Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma[J].Am J Obstet Gynecol,1990(162):427-429.
[13]Wright J D,Barrena Medel N I,Sehouli J,et al.Contemporary management of endometrial cancer[J].Lancet,2012(379):1352-1360.
[14]Edge S B,Byrd D R,Compton C C.AJCC Cancer Staging Manual[M].7th edition.New York:Springer,2010.
[15]Pecorelli S.Revised FIGO staging for carcinoma of the vulva,cervix,and endometrium[J].Int J Gynaecol Obstet,2009(105):103-104.
[16]Kim C H,Soslow R A,Park K J,et al.Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging[J].Int J Gynecol Cancer,2013(23):964-970.
[17]Soliman P T,Frumovitz M,Spannuth W,et al.Lymphadenectomy during endometrial cancer staging:practice patterns among gynecologic oncologists[J].Gynecol Oncol,2010(119):291-294.
[18]Todo Y,Kato H,Kaneuchi M,et al.Survival eあect of para-aortic lymphadenectomy in endometrial caNeubauer NL,Lurain JR.The role of lymphadenectomy in surgical staging of endometrial cancer.Int J Surg Oncol 2011;2011:814649.ncer(SEPAL study):a retrospective cohort analysis[J].Lancet,2010(375):1165-1172.
[19]Barlin J N,Khoury-Collado F,Kim C H,et al.The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging:beyond removal of blue nodes[J].Gynecol Oncol,2012(125):531-535.(https://www.daowen.com)
[20]Scalici J,Laughlin B B,Finan M A,et al.The trend towards minimally invasive surgery(MIS)for endometrial cancer:an ACSNSQIP evaluation of surgical outcomes[J].Gynecol Oncol,2015(136):512- 515.
[21]Fader A N,Weise R M,Sinno A K,et al.Utilization of Minimally Invasive Surgery in Endometrial Cancer Care:A Quality and Cost Disparity[J].Obstet Gynecol,2016(127):91-100.
[22]He H,Zeng D,Ou H,et al.Laparoscopic treatment of endometrial cancer:systematic review[J].J Minim Invasive Gynecol,2013(20):413-423.
[23]Gunderson C C,Fader A N,Carson K A,et al.Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma:a systematic review[J].Gynecol Oncol,2012(125):477-482.
[24]Hubbs J L,Saig R M,Abaid L N,et al.Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma[J].Obstet Gynecol,2013(121):1172-1180.
[25]Park J Y,Kim D Y,Kim J H,et al.Long-term oncologic outcomes after fertilitysparing management using oral progestin for young women with endometrial cancer(KGOG 2002)[J].Eur J Cancer,2013(49):868-874.
[26]Altman A D,Thompson J,Nelson G,et al.Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma:a retrospective study[J].J Obstet Gynaecol Can,2012(34):664-672.
[27]Homesley H D,Filiaci V,Gibbons S K,et al.A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel:A Gynecologic Oncology Group study[J].Gynecol Oncol,2009(112):543-552.
[28]Creutzberg C L,van Stiphout R G,Nout R A,et al.Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer:a pooled analysis of PORTEC-1 and PORTEC-2 trials[J].Int J Radiat Oncol Biol Phys,2015(91):530-539.
[29]Morrow C P,Bundy B N,Kurman R J,et al.Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium:a Gynecologic Oncology Group study[J].Gynecol Oncol,1991(40):55-65.
[30]Creutzberg C L,Nout R A,Lybeert M L,et al.Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma[J].Int J RadiatOncol Biol Phys,2011(81):e631-638.
[31]Small W,Jr.,Beriwal S,Demanes D J,et al.American Brachytherapy Society consensus guidelines for adjuvant vaginal cuあ brachytherapy after hysterectomy[J].Brachytherapy,2012(11):58-67.
[32]Johnson N,Cornes P.Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer:systematic review and meta-analysis[J].BJOG,2007(114):1313-1320.
[33]Park H J,Nam E J,Kim S,et al.The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer:a meta-analysis[J].Eur J Obstet Gynecol Reprod Biol,2013(170):39-44.
[34]Johnson N,Bryant A,Miles T,et al.Adjuvant chemotherapy for endometrial cancer after hysterectomy[J].Cochrane Database Syst Rev,2011(84):CD003115.
[35]Boer de S M,Nout R A,Jurgenliemk-Schulz I M,et al.Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship:Results From the Randomized PORTEC-2 Trial[J].Int J Radiat Oncol Biol Phys,2015(93):797-809.
[36]Dowdy S C,Mariani A,Cliby W A,et al.Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer:technique and analysis of outcomes[J].Gynecol Oncol,2006(101):280-286.
[37]Singh M,Zaino R J,Filiaci V J,et al.Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma:a Gynecologic Oncology Group Study[J].Gynecol Oncol,2007(106):325-333.
[38]Humber C E,Tierney J F,Symonds R P,et al.Chemotherapy for advanced,recurrent or metastatic endometrial cancer:a systematic review of Cochrane collaboration[J].Ann Oncol,2007(18):409-420.